share_log

Processa Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Processa Pharmaceuticals | 10-Q: Q2 2024 Earnings Report

Processa Pharmaceuticals | 10-Q：2024财年二季报
美股SEC公告 ·  08/13 16:20

Moomoo AI 已提取核心信息

Processa Pharmaceuticals, Inc. (Processa), a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company's cash and cash equivalents increased to $5,571,120 from $4,706,197 at the end of the previous year. Total assets rose to $7,600,976, up from $5,786,643. Research and development expenses for the quarter were $1,730,444, slightly up from $1,688,164 in the same period last year, while general and administrative expenses increased to $1,351,580 from $1,026,301. The company reported a net loss of $3,010,326 for the quarter, compared to a net loss of $2,612,565 in the previous year. The net loss per common share was $1.01, compared to $1.94 in the same quarter of the previous year. Processa continues to focus on the development of its Next Generation Chemotherapy (NGC) drugs, with a Phase 2 trial for NGC-Cap in breast cancer expected to begin shortly. The company's future plans include advancing its pipeline of NGC proprietary small molecule oncology drugs and exploring options to monetize non-core drug assets through out-licensing or partnerships.
Processa Pharmaceuticals, Inc. (Processa), a clinical-stage biopharmaceutical company, reported its financial results for the quarter ended June 30, 2024. The company's cash and cash equivalents increased to $5,571,120 from $4,706,197 at the end of the previous year. Total assets rose to $7,600,976, up from $5,786,643. Research and development expenses for the quarter were $1,730,444, slightly up from $1,688,164 in the same period last year, while general and administrative expenses increased to $1,351,580 from $1,026,301. The company reported a net loss of $3,010,326 for the quarter, compared to a net loss of $2,612,565 in the previous year. The net loss per common share was $1.01, compared to $1.94 in the same quarter of the previous year. Processa continues to focus on the development of its Next Generation Chemotherapy (NGC) drugs, with a Phase 2 trial for NGC-Cap in breast cancer expected to begin shortly. The company's future plans include advancing its pipeline of NGC proprietary small molecule oncology drugs and exploring options to monetize non-core drug assets through out-licensing or partnerships.
临床阶段生物制药公司Processa Pharmaceuticals, Inc.（Processa）报告了2024年6月30日结束的季度财务状况。该公司的现金及现金等价物从上年末的$4,706,197增至$5,571,120。总资产从$5,786,643上升至$7,600,976。本季度的研发费用为$1,730,444，略高于上年同期的$1,688,164，而总行政费用从$1,026,301增加至$1,351,580。该公司报告本季度净亏损为$3,010,326，而上年同期净亏损为$2,612,565。每股普通股净亏损为$1.01，而上年同季度为$1.94。Processa继续专注于其Next Generation Chemotherapy (NGC)药物的开发，预计很快将开始NGC-Cap用于乳腺癌的第二阶段试验。公司的未来计划包括推进其NGC专有小分子肿瘤药物流水线并探索通过外部授权或合作伙伴关系获取非核心药物资产的获利选择。
临床阶段生物制药公司Processa Pharmaceuticals, Inc.（Processa）报告了2024年6月30日结束的季度财务状况。该公司的现金及现金等价物从上年末的$4,706,197增至$5,571,120。总资产从$5,786,643上升至$7,600,976。本季度的研发费用为$1,730,444，略高于上年同期的$1,688,164，而总行政费用从$1,026,301增加至$1,351,580。该公司报告本季度净亏损为$3,010,326，而上年同期净亏损为$2,612,565。每股普通股净亏损为$1.01，而上年同季度为$1.94。Processa继续专注于其Next Generation Chemotherapy (NGC)药物的开发，预计很快将开始NGC-Cap用于乳腺癌的第二阶段试验。公司的未来计划包括推进其NGC专有小分子肿瘤药物流水线并探索通过外部授权或合作伙伴关系获取非核心药物资产的获利选择。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间